Kymera Therapeutics, Inc. (KYMR)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $106.68
- As of
Kresmion compiles this page from KYMR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Kymera Therapeutics, Inc. (KYMR): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-05.
See the full KYMR dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for KYMR on one page. Preview it with sample data, then open it live with a free account.
Preview the KYMR dossierActive signals for KYMR
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +148% to KYMR (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +121% to KYMR (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +726% to KYMR (2026Q2)
- mediumNEW_POSITION
D. E. Shaw & Co., Inc. new position in KYMR
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 15.3%, EPS $-0.62 vs $-0.7316 estimate
FREE, NO ACCOUNT
Every signal on KYMR, as it fires
You are seeing 5 of 10 signals recorded on KYMR since 2026-05-30.
The five above landed across 2 days. The other 5 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in KYMR (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 501575104 · 2026Q2 | $42.6M | 0.03% | , |
| CITADEL ADVISORS LLCCUSIP 501575104 · 2026Q2 | $12.8M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 501575104 · 2026Q2 | $321K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, KYMR
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
KYMR against its peers
KYMR's operating margin of -891.1% ranks in the 9th percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-03-31.
| Metric | KYMR | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 39.2M USD | 502M USD | 19 | 17 |
| Operating margin | -891.1% | -31.3% | 9 | 15 |
| Net margin | -794.0% | -30.1% | 16 | 15 |
| Return on equity | -19.7% | -28.5% | 63 | 19 |
| P / E | n/a | 30.6x | n/a | 5 |
| 1 year | 78.1% | 63.9% | 71 | 18 |
Peers (23): PTGX, CRNX, ARWR, CYTK, NUVL, KRYS, TGTX, CAI, APGE, BMRN, MDGL, SYRE, ABVX, IBRX, PCVX, IONS, PRAX, HALO, ALKS, BBIO, IOVA, KOD, IMVT. Left out: BCHMY (no annual filing), SBMFF (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (KYMR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow KYMR on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to KYMR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.